Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its news flow is heavily centered on TSHA-102, a self-complementary, intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
On this TSHA news page, readers can follow company announcements about clinical progress in the REVEAL Phase 1/2 and pivotal trials, as well as the ASPIRE safety-focused study in younger females with Rett syndrome. Taysha regularly reports on enrollment status, dosing milestones, interim and longer-term safety and efficacy data, and supplemental analyses of functional outcomes and developmental milestones achieved post-TSHA-102.
Investors and followers of TSHA stock will also find regulatory updates, such as the FDA’s Breakthrough Therapy designation for TSHA-102 and alignment on pivotal trial protocols and statistical analysis plans intended to support a future Biologics License Application. Additional news items include financial results, capital-raising activities, amendments to at-the-market equity programs, and inducement grants of stock options under the company’s inducement plan.
Because Rett syndrome is a rare neurodevelopmental disorder with no approved disease-modifying therapies that address its genetic root cause, developments from Taysha’s TSHA-102 program are closely watched by patients, caregivers and market participants. This page aggregates these company-issued updates so that readers can monitor how clinical data, regulatory interactions and corporate actions may shape the trajectory of TSHA-102 and the broader Taysha pipeline over time.
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two upcoming events: the International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Symposium and the ASCEND Rett Syndrome National Summit, both in Nashville, Tennessee, from April 26 to 30, 2022. Key presentations will include safety assessments of a miniMECP2 AAV9 vector for gene therapy and insights on caregiver perspectives. Taysha emphasizes its commitment to developing AAV-based gene therapies for monogenic CNS diseases, aiming to innovate treatments for both rare and common conditions.
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2022. Key executives, including the CEO, CTO, and CMO, will join a panel discussion at 12:00 pm ET focusing on AAV gene therapy manufacturing standards from registration-targeted trials. Following this, a fireside chat will take place at 1:00 pm ET. Taysha is committed to developing AAV-based gene therapies for central nervous system diseases, aiming to translate research into effective treatments.
Taysha Gene Therapies (TSHA) reported significant changes in its strategic focus, prioritizing programs for giant axonal neuropathy (GAN) and Rett syndrome, affecting 5,000 and 350,000 patients respectively. A workforce reduction of 35% aims to enhance operational efficiency as clinical activities for other programs will be paused. Financial results show a net loss of $174.5 million for 2021 and R&D expenses increased by $100 million. Despite challenges, existing cash and financing are expected to extend the cash runway into Q4 2023.
Taysha Gene Therapies has announced the initiation of clinical development for TSHA-102, a gene therapy for Rett syndrome, following approval of the Clinical Trial Application by Health Canada. TSHA-102, utilizing the novel miRARE platform, aims to regulate transgene expression safely. Promising preclinical results were reported, showing improved survival and function in mouse models and a favorable safety profile in non-human primates. Preliminary clinical data are expected by the end of 2022, marking a significant milestone in treating this severe neurodevelopmental disorder affecting over 350,000 patients globally.
Taysha Gene Therapies (Nasdaq: TSHA) has announced plans to report its financial results for the fourth quarter and full year ending December 31, 2021. A corporate update conference call is scheduled for Thursday, March 31, 2022, at 8:00 AM Eastern Time. The company is focused on developing AAV-based gene therapies for treating monogenic diseases in the central nervous system. Taysha combines expertise in drug development with the UT Southwestern Gene Therapy Program to create a robust pipeline aimed at curing these diseases.
Taysha Gene Therapies (Nasdaq: TSHA) will participate in the Guggenheim Genomic Medicines and Rare Disease Day Conference on April 1, 2022, at 4:00 PM ET, and the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 11:45 AM ET. The events will feature discussions led by key executives including RA Session II, Suyash Prasad, and Kamran Alam. Taysha focuses on developing AAV-based gene therapies aimed at curing monogenic diseases of the CNS.
Taysha Gene Therapies (Nasdaq: TSHA) announced participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference. The first chat, focusing on AAV-based Gene Therapy, will take place on March 14, 2022 at 11:00 am ET. The second chat is scheduled for March 15, 2022 at 1:20 pm ET. The events will feature the company's leadership, including the President, Founder, and CEO, and will be accessible via webcast on the Taysha corporate website.
Taysha Gene Therapies (TSHA) announced promising clinical safety data for its gene therapy targeted at CLN7 Batten disease, presented at the 18th Annual WORLD Symposium. The trial achieved the highest intrathecal dose ever delivered in humans, demonstrating a favorable safety profile with no adverse immune responses or dorsal root ganglia inflammation. The trial, ongoing at UT Southwestern, aims to establish safety and tolerability, with potential implications for a serious, currently untreated disease affecting approximately 4,000 patients globally.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has reported promising clinical findings for its gene therapy TSHA-120, aimed at treating giant axonal neuropathy (GAN). The data revealed a clinically significant improvement in MFM32 scores across all therapeutic cohorts after one and three years. Specifically, the high dose cohort showed a 5-point improvement compared to an 8-point decline in natural history by Year 1. Additionally, nerve regeneration was confirmed in biopsies. TSHA-120 demonstrated a favorable safety profile over 53 patient-years.
Taysha Gene Therapies (TSHA) reported positive initial data for TSHA-101, a gene therapy for GM2 gangliosidosis. Patient 1 with Sandhoff disease achieved Hex A enzyme activity at 190% of normal by Month 1 and 288% by Month 3, translating to 58-fold above the asymptomatic level. Patient 2 with Tay-Sachs saw a 5-fold increase at Month 1. This is the first support for a bicistronic vector in humans, aiming to normalize enzyme activity. The therapy was well-tolerated, with further clinical updates expected by year-end.